{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T04:32:07Z","timestamp":1786422727291,"version":"build-2736575974"},"reference-count":24,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T00:00:00Z","timestamp":1786406400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Mantle cell lymphoma (MCL) is an aggressive B-cell lymphoma with limited treatment options for relapsed\/refractory (R\/R) cases. CAR T-cell therapy and CD20\u00d7CD3 bispecific antibodies are promising immunotherapies, but no study has systematically compared their efficacy and safety in R\/R MCL.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This systematic review and meta-analysis was conducted in accordance with the PRISMA 2020 guidelines and registered in PROSPERO (CRD42024622564). A comprehensive search of PubMed, Embase, and the Cochrane Library (from inception to October 27, 2024) was performed to identify studies evaluating CAR T-cell therapy and bispecific antibodies in R\/R MCL (third-line or later). Random-effects and fixed-effects models were used to calculate pooled complete response (CR) rates, overall response (OR) rates, and Grade \u22653 adverse events. Sensitivity analyses were conducted to assess the robustness of the results.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Five studies (237 patients) were included. Pooled CR rates were 0.63(95% CI, 0.51-0.74)for bispecific antibodies and 0.70(95%CI, 0.63-0.77) for CAR T-cell therapy (P &amp;lt;0.05). OR rates were similar (0.75 vs. 0.88). Grade \u22653 cytokine release syndrome rates were comparable (0.06 vs. 0.06), but neurotoxicity cannot be compared.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>CAR T-cell therapy demonstrated higher CR rates versus bispecific antibodies, supporting their role as effective third-line treatments for R\/R MCL. Randomized trials are needed to confirm these findings.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Systematic Review Registration<\/jats:title>\n                    <jats:p>\n                      <jats:ext-link>https:\/\/www.crd.york.ac.uk\/prospero\/<\/jats:ext-link>\n                      , identifier CRD42024622564.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fonc.2026.1860307","type":"journal-article","created":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T04:21:10Z","timestamp":1786422070000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["CAR T-cell vs bispecific antibodies in relapsed\/refractory mantle cell lymphoma: a systematic review and meta-analysis"],"prefix":"10.3389","volume":"16","author":[{"given":"Meng-jiao","family":"Li","sequence":"first","affiliation":[{"name":"Department of Hematology, The General Hospital of Western Theater Command","place":["Chengdu, Sichuan, China"]},{"name":"Department of Clinical Medicine, North Sichuan Medical College","place":["Nanchong, Sichuan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ling","family":"Qiu","sequence":"additional","affiliation":[{"name":"Department of Hematology, The General Hospital of Western Theater Command","place":["Chengdu, Sichuan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Hematology, The General Hospital of Western Theater Command","place":["Chengdu, Sichuan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cai-yang","family":"Li","sequence":"additional","affiliation":[{"name":"Institute of Basic Medicine, North Sichuan Medical College","place":["Nanchong, Sichuan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"He","sequence":"additional","affiliation":[{"name":"Department of Hematology, The General Hospital of Western Theater Command","place":["Chengdu, Sichuan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan-ling","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Hematology, The General Hospital of Western Theater Command","place":["Chengdu, Sichuan, China"]},{"name":"Department of Clinical Medicine, North Sichuan Medical College","place":["Nanchong, Sichuan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ya-li","family":"Cen","sequence":"additional","affiliation":[{"name":"Department of Hematology, The General Hospital of Western Theater Command","place":["Chengdu, Sichuan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shi-hui","family":"Ren","sequence":"additional","affiliation":[{"name":"Department of Hematology, The General Hospital of Western Theater Command","place":["Chengdu, Sichuan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao","family":"Yao","sequence":"additional","affiliation":[{"name":"Department of Hematology, The General Hospital of Western Theater Command","place":["Chengdu, Sichuan, China"]},{"name":"Institute of Basic Medicine, North Sichuan Medical College","place":["Nanchong, Sichuan, China"]},{"name":"College of Medicine, Southwest Jiaotong University","place":["Chengdu, Sichuan, China"]},{"name":"Reproductive Medicine Center, The General Hospital of Western Theater Command","place":["Chengdu, Sichuan, China"]},{"name":"Tissue Stress Injury and Functional Repair Key Laboratory of Sichuan Province","place":["Chengdu, Sichuan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fang-yi","family":"Fan","sequence":"additional","affiliation":[{"name":"Department of Hematology, The General Hospital of Western Theater Command","place":["Chengdu, Sichuan, China"]},{"name":"Department of Clinical Medicine, North Sichuan Medical College","place":["Nanchong, Sichuan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,8,11]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-07-797019","article-title":"Expression of TP53 is associated with the outcome of MCL independent of MIPI and Ki-67 in trials of the European MCL Network","volume":"131","author":"Aukema","year":"2018","journal-title":"Blood"},{"key":"B2","doi-asserted-by":"crossref","DOI":"10.1007\/978-3-030-94353-0_13","article-title":"Mantle cell lymphoma","volume-title":"The Ebmt\/Eha CAR-T Cell Handbook","author":"Milpied","year":"2022"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdx223","article-title":"Newly diagnosed and relapsed mantle cell lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"28","author":"Dreyling","year":"2017","journal-title":"Ann Oncol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1038\/s41409-017-0067-3","article-title":"Long-term outcome analysis of reduced-intensity allogeneic stem cell transplantation in patients with mantle cell lymphoma: a retrospective study from the EBMT Lymphoma Working Party","volume":"53","author":"Robinson","year":"2018","journal-title":"Bone Marrow Transplant"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-10-673145","article-title":"Postibrutinib outcomes in patients with mantle cell lymphoma","volume":"127","author":"Martin","year":"2016","journal-title":"Blood"},{"key":"B6","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1186\/s12943-023-01755-5","article-title":"CAR T-Cell therapy for the management of mantle cell lymphoma","volume":"22","author":"Huang","year":"2023","journal-title":"Mol Cancer"},{"key":"B7","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.3390\/jcm10061207","article-title":"Relapsed mantle cell lymphoma: Current management, recent progress, and future directions","volume":"10","author":"Bond","year":"2021","journal-title":"J Clin Med"},{"key":"B8","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1186\/s13045-023-01496-4","article-title":"Beyond Bruton's tyrosine kinase inhibitors in mantle cell lymphoma: bispecific antibodies, antibody-drug conjugates, CAR T-cells, and novel agents","volume":"16","author":"Jain","year":"2023","journal-title":"J Hematol Oncol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/S2152-2650(24)01600-8","article-title":"MCL-341 Glofitamab monotherapy in patients with heavily pretreated relapsed\/refractory (R\/R) mantle cell lymphoma (MCL): Updated analysis from a phase 1\/2 study","volume":"24","author":"Phillips","year":"2024"},{"key":"B10","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1182\/blood-2023-174956","article-title":"Fixed duration mosunetuzumab plus polatuzumab vedotin has promising efficacy and a manageable safety profile in patients with BTKi relapsed\/refractory mantle cell lymphoma: Initial results from a phase Ib\/II study","volume":"142","author":"Wang","year":"2023","journal-title":"Blood"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1200\/jco.21.02370","article-title":"Three-year follow-up of KTE-X19 in patients with relapsed\/refractory mantle cell lymphoma, including high-risk subgroups, in the ZUMA-2 study","volume":"41","author":"Wang","year":"2023","journal-title":"J Clin Oncol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1200\/jco.23.02214","article-title":"Lisocabtagene maraleucel in relapsed\/refractory mantle cell lymphoma: Primary analysis of the mantle cell lymphoma cohort from TRANSCEND NHL 001, a phase I multicenter seamless design study","volume":"42","author":"Wang","year":"2024","journal-title":"J Clin Oncol"},{"key":"B13","doi-asserted-by":"publisher","first-page":"2827","DOI":"10.1182\/blood-2021-153087","article-title":"Real-world evidence of brexucabtagene autoleucel for the treatment of relapsed or refractory mantle cell lymphoma","volume":"138","author":"Iacoboni","year":"2021","journal-title":"Blood"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.21037\/tcr-23-1396","article-title":"A STEP ahead for CAR-T cell therapy of large B cell lymphoma: understanding the molecular determinants of resistance","volume":"12","author":"Mouhssine","year":"2023","journal-title":"Transl Cancer Res"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1002\/eji.70123","article-title":"Downregulation of CD19 expression associates with mantle cell lymphoma relapse following CAR-T cell therapy","volume":"56","author":"Peruzzi","year":"2026","journal-title":"Eur J Immunol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1110028","article-title":"Predictive short\/long-term efficacy biomarkers and\u00a0resistance mechanisms of CD19-directed CAR-T immunotherapy in relapsed\/refractory B-cell lymphomas","volume":"14","author":"Xu","year":"2023","journal-title":"Front Immunol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2026.1692287","article-title":"CD19-negative relapse after CAR-T cell therapy: mechanisms of antigen escape and lineage switch","volume":"17","author":"Huang","year":"2026","journal-title":"Front Immunol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2026.1727926","article-title":"Targeting CAR-T cell exhaustion in non-Hodgkin lymphoma: mechanistic insights and emerging clinical strategies","volume":"17","author":"Rao","year":"2026","journal-title":"Front Immunol"},{"key":"B19","doi-asserted-by":"publisher","first-page":"201099","DOI":"10.1016\/j.omton.2025.201099","article-title":"CAR-T cell exhaustion in B cell lymphoma: Current status, mechanisms, and potential solutions","volume":"34","author":"Zhao","year":"2026","journal-title":"Mol Ther Oncol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1111\/ejh.14103","article-title":"Tumor microenvironment and CAR-T cell immunotherapy in B-cell lymphoma","volume":"112","author":"Cai","year":"2024","journal-title":"Eur J Haematol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2023.2258244","article-title":"Functional drivers of resistance to anti-CD19 CAR-T cell therapy in diffuse large B cell lymphoma","volume":"64","author":"Newsam","year":"2023","journal-title":"Leuk Lymphoma"},{"key":"B22","doi-asserted-by":"publisher","first-page":"794","DOI":"10.3390\/cells15090794","article-title":"Molecular mechanisms of resistance to bispecific antibodies in diffuse large B-cell lymphoma","volume":"15","author":"Maher","year":"2026","journal-title":"Cells"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtct.2023.04.007","article-title":"Mechanisms of resistance and treatment of relapse after CAR T-cell therapy for large B-cell lymphoma and multiple myeloma","volume":"29","author":"Rejeski","year":"2023","journal-title":"Transplant Cell Ther"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2025-3300","article-title":"Overcoming resistance to bispecific antibodies through epigenetic priming in B-cell lymphoma","volume":"146","author":"Piorczynski","year":"2025","journal-title":"Blood"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1860307\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T04:21:12Z","timestamp":1786422072000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1860307\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,11]]},"references-count":24,"alternative-id":["10.3389\/fonc.2026.1860307"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1860307","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,11]]},"article-number":"1860307"}}